ISSN 1443-850X

Bioshares

3 May 2021
Edition 890

Delivering independent investment research to investors on Australian biotech, pharma and healthcare companies

Companies covered: **AVR, Cash Flow Analysis**

	Bioshares Portfolio
Year 1 (May '01 - May '02)	21.2%
Year 2 (May '02 - May '03)	-9.4%
Year 3 (May '03 - May '04)	70.6%
Year 4 (May '04 - May '05)	-16.3%
Year 5 (May '05 - May '06)	77.8%
Year 6 (May '06 - May '07)	17.4%
Year 7 (May '07 - May '08)	-35.8%
Year 8 (May '08 - May '09)	-7.4%
Year 9 (May '09 - May '10)	50.2%
Year 10 (May '10 - May'11)	45.4%
Year 11 (May '11 - May '12)	-18.0%
Year 12 (May '12 - May '13)	3.1%
Year 13 (May '13 - May '14)	26.6%
Year 14 (May '14 - May '15)	23.0%
Year 15 (May '15 - May '16)	33.0%
Year 16 (May '16 - May '17)	16.8%
Year 17 (May '17 - May '18)	-7.1%
Year 18 (May '18 - May '19)	-2.3%
Year 19 (May '19 - May '20)	39.5%
Year 20 (May '20 - Current)	84.0%
Cumulative Gain	1904%
Av. Annual gain (20 yrs)	20.6%

Bioshares is published by Blake Industry & Market Analysis Pty Ltd.

Blake Industry & Market Analysis Pty Ltd
ACN 085 334 292
PO Box 193
Richmond Vic 3121
AFS Licence No. 258032
Enquiries for *Bioshares*
Ph: (03) 9326 5382
Fax: DISCONTINUED
Email: info[at}bioshares.com.au

David Blake - Editor/Analyst
Ph: (03) 9326 5382
Email: david[at]bioshares.com.au

Mark Pachacz - Editor/Analyst
Ph: 0403 850 425
Email: mark[at]bioshares.com.au

Individual Subscriptions (48 issues/year)
$550 (Inc.GST)
Edition Number 890 (3 May 2021)

Extract from Bioshares –

Anteris Meets Catheter Milestone

An aortic valve replacement undertaken using the less invasive transcatheter approach (no open heart surgery) has three key aspects; the valve, the catheter system, and the surgical technique required to deploy the catheter to implant the valves.

Anteris Technologies (AVR: $9.55) has reached a major milestone now that it has locked in the key components of its catheter system, the ComASUR Transfemoral Delivery System. Furthermore, the company believes that the ComASUR novel alignment feature gives it a point of difference to other current marketed products.

The alignment feature refers to the ability of the surgeon to align the commissures of the replacement valve to the native valve. Noting that an aortic valve comprises of three leaflets, the commissure is space between between each cusp where it is anchored to the aortic wall.

Anteris has completed animal studies of the COMASUR delivery system, which were designed to show that the system could access the arterial vasculature, an obvious but critical step, and then track though the aortic arch to the aortic valve. The company said "post-implant echocardiography and CT scan confirmed the functionality of the DurAVR THV with stable positioning and good hemodynamic function."

This latest milestone is relevant to the company's planned early feasibility study (in humans) which it intends to commence later in the year, but is working to satisfy the FDA's requirements for the study.

The company is progressing slowly through a 15-patient study in Belgium in which its novel 3D device, implanted surgically, has to date made positive progress.

The commercial attractiveness of Anteris' novel 3D aortic valve stems from its potential for superior hemodynamic performance, the ADAPT tissue processing technology which delivers non-calcification benefits (>10 years, or more), and hence the potential for its use in younger patients.

The development of a functional catheter places Anteris' offering on par with existing valves implanted using the transcatheter approach. The two majpr transcatheter valves (TAVR) include Medtronic's CoreValve and Edwards Life Sciences Sapien XT.

Summary

Anteris continues to make both positive and necessary progress towards the gaining of approval for its feasibility study of its transcatheter delivered aortic valve replacement, DurAVR. The design and other requirements of the study, while unknown, sit as a risk for the stock.

Continued over

– Anteris cont'd

While the company retained a low cash balance at the end of the March quarter of $1.6M, it has accessed its $20 million funding facility set up with Mercer Street Global Opportunities Fund in the March quarter. The balance of the facility is now $15.95 million.

Anteris is capitalised at $63 million.

Bioshares recommendation: **Speculative Buy Class A**

Bioshares

How Bioshares Rates Stocks

For the purpose of valuation, Bioshares divides biotech stocks into two categories. The first group are stocks with existing positive cash flows or close to producing positive cash flows. The second group are stocks without near term positive cash flows, history of losses, or at early stages of commercialisation. In this second group, which are essentially speculative propositions, Bioshares grades them according to relative risk within that group, to better reflect the very large spread of risk within those stocks. For both groups, the rating "Take Some Profits" means that investors may re-weight their holding by selling between 25%-75% of a stock.

Group A

Stocks with existing positive cash flows or close to producing positive cash flows.

Buy	CMP is 20% < Fair Value
Accumulate	CMP is 10% < Fair Value
Hold	Value = CMP
Lighten	CMP is 10% > Fair Value
Sell	CMP is 20% > Fair Value

(CMP–Current Market Price)

Group B

Stocks without near term positive cash flows, history of losses, or at early stages of commercialisation.

Speculative Buy – Class A
These stocks will have more than one technology, product or investment in development, with perhaps those same technologies offering multiple opportunities. These features, coupled to the presence of alliances, partnerships and scientific advisory boards, indicate the stock is relative less risky than other biotech stocks.

Speculative Buy – Class B
These stocks may have more than one product or opportunity, and may even be close to market. However, they are likely to be lacking in several key areas. For example, their cash position is weak, or management or board may need strengthening.

Speculative Buy – Class C
These stocks generally have one product in development and lack many external validation features.

Speculative Hold – Class A or B or C

Sell

Corporate Subscribers: Cogstate, LBT Innovations, Opthea, ResApp Health, Pharmaxis, Dimerix, Adalta, Actinogen Medical, Patrys, Cyclopharm, Antisense Therapeutics, Imugene, Exopharm, Immutep, Neuroscientific Biopharmaceuticals, Invex Therapeutics, Anteris Technologies, Chimeric Therapeutics